Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXSNASDAQ:ARDSNASDAQ:ENVBNASDAQ:JAN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.12$0.05$0.00▼$0.78$5.13M1.186,238 shs171 shsARDSAridis Pharmaceuticals$0.00$0.00$0.00▼$0.08$5K12.097,927 shs14,969 shsENVBEnveric Biosciences$1.26+0.8%$1.27$1.01▼$11.55$3.11M0.53771,139 shs125,017 shsJANJanOne$2.57$0.22▼$5.26$20.03M2.16229,417 shs139,500 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals0.00%+280.70%+220.80%+301.00%-51.90%ARDSAridis Pharmaceuticals0.00%0.00%0.00%0.00%-99.86%ENVBEnveric Biosciences0.00%+1.61%-6.67%-27.59%-87.48%JANJanOne0.00%0.00%0.00%0.00%-2.62%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AARDSAridis PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AENVBEnveric Biosciences1.56 of 5 stars3.52.00.00.00.00.01.3JANJanOneN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXSAyala Pharmaceuticals 0.00N/AN/AN/AARDSAridis Pharmaceuticals 0.00N/AN/AN/AENVBEnveric Biosciences 3.00Buy$10.00693.65% UpsideJANJanOne 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXSAyala Pharmaceuticals$3.24M1.58N/AN/A($2.06) per share-0.06ARDSAridis Pharmaceuticals$3.09M0.00N/AN/AN/A∞ENVBEnveric BiosciencesN/AN/AN/AN/A$2.35 per shareN/AJANJanOne$39.61M0.00N/AN/A($0.67) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXSAyala Pharmaceuticals-$48.07M-$7.98N/A∞N/AN/AN/AN/AN/AARDSAridis Pharmaceuticals-$30.37MN/A0.00∞N/AN/AN/AN/AN/AENVBEnveric Biosciences-$9.57M-$38.38N/AN/AN/AN/A-250.28%-195.57%8/11/2025 (Estimated)JANJanOne-$7.81MN/A0.00N/AN/AN/A-359.71%-70.26%N/ALatest JAN, ADXS, ENVB, and ARDS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ENVBEnveric Biosciences-$3.45-$1.22+$2.23-$1.22N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AARDSAridis PharmaceuticalsN/AN/AN/AN/AN/AENVBEnveric BiosciencesN/AN/AN/AN/AN/AJANJanOneN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXSAyala PharmaceuticalsN/AN/AN/AARDSAridis PharmaceuticalsN/AN/AN/AENVBEnveric BiosciencesN/A4.084.08JANJanOneN/A0.150.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXSAyala Pharmaceuticals7.18%ARDSAridis Pharmaceuticals9.65%ENVBEnveric Biosciences13.82%JANJanOne6.27%Insider OwnershipCompanyInsider OwnershipADXSAyala Pharmaceuticals0.63%ARDSAridis Pharmaceuticals5.50%ENVBEnveric Biosciences1.10%JANJanOne3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXSAyala Pharmaceuticals2042.63 million42.36 millionNot OptionableARDSAridis Pharmaceuticals3053.32 million50.39 millionNot OptionableENVBEnveric Biosciences202.47 million2.45 millionNot OptionableJANJanOne1708.98 million8.71 millionNot OptionableJAN, ADXS, ENVB, and ARDS HeadlinesRecent News About These CompaniesCSE Bulletin: New Listing - Giant Mining Corp. 14JAN2026 Warrants (BFG.WT.B)May 20, 2025 | newsfilecorp.comBiotech Company Loses Insurance Appeal on SEC Probe ExpensesMay 9, 2025 | news.bloomberglaw.comAppeals Court Grills Biotech, Insurer on SEC Probe CoverageApril 9, 2025 | news.bloomberglaw.comNew Dayton-based publicly traded company in the works with prominent local leaderOctober 7, 2024 | bizjournals.comL-L League field hockey capsules: Who's who in Section 2 for 2024August 27, 2024 | lancasteronline.comJANONE CONFIRMS NAME CHANGE TO ALT5 SIGMA CORPORATION AND NEW TICKER SYMBOL TO ALTSJuly 12, 2024 | prnewswire.comJanOne Announces Plan to Enhance Stockholder Value Through Strategic RealignmentJuly 10, 2024 | prnewswire.com3 Fintech Stocks to Sell in July Before They Crash & BurnJuly 8, 2024 | investorplace.comJanOne Appoints Vay Tham as its Chief Revenue Officer and President of its Fintech Subsidiary, ALT5 SigmaJune 26, 2024 | prnewswire.comALT5 SIGMA, A JANONE COMPANY, ADDS PREPAID VISA®️ CARD INTEGRATION TO ALT5 SETTLEMENT PLATFORMJune 25, 2024 | prnewswire.comJanOne's Subsidiary, Alt5, Reports 91% year over year increase in Transaction Volume to US $289 million for April and May 2024June 13, 2024 | prnewswire.comALT5 Sigma, a wholly-owned subsidiary of JanOne, Launches ALT5 Settlement Platform aimed at the untapped $27.3 Billion Global Digital Content Creation MarketJune 11, 2024 | prnewswire.comJanOne Inc. added to the Russell Microcap® IndexJune 3, 2024 | prnewswire.comALT 5 Sigma, a wholly-owned subsidiary of JanOne to Present at the iFX Expo, the World's largest online trading conference and tradeshowMay 28, 2024 | prnewswire.comIt’s not the right time to quit: JanOne Inc (JAN) StockMay 27, 2024 | bovnews.comJanOne Inc. (JAN) Stock Price, News, Quote & History - Yahoo FinanceMay 16, 2024 | finance.yahoo.comJanOne Closes Acquisition of ALT 5 Sigma Inc., a Leading Next Generation Blockchain FintechMay 16, 2024 | prnewswire.comWhy Tevogen Bio Holdings Stock Is Moving Higher TodayMay 13, 2024 | msn.comJanOne To Buy Block Chain Fintech Provider ALT 5 Sigma In All-stock Deal; JAN Up In Pre-marketMay 13, 2024 | markets.businessinsider.comJanone To Acquire Blockchain Fintech Provider ALT 5 SigmaMay 12, 2024 | crowdfundinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJAN, ADXS, ENVB, and ARDS Company DescriptionsAyala Pharmaceuticals NASDAQ:ADXS$0.12 0.00 (0.00%) As of 06/18/2025 09:30 AM EasternAyala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.Aridis Pharmaceuticals NASDAQ:ARDS$0.0001 0.00 (0.00%) As of 06/18/2025 01:51 PM EasternAridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.Enveric Biosciences NASDAQ:ENVB$1.26 +0.01 (+0.80%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.25 -0.01 (-1.19%) As of 06/18/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.JanOne NASDAQ:JANJanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through Biotechnology and Recycling segments. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
